Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4501
PUT
Quantum Computing Inc
QUBT
$1.85B
| $101K | ﹤0.01% |
+9,800
| New | +$139K |
2025 Q4
0 quarters
|
|
4502
FitLife Brands
FTLF
$86.6M
| $100K | ﹤0.01% |
6,164
+538
| +10% | +$9.89K |
2024 Q3
5 quarters
|
|
|
ETOR
4503
eToro Group
ETOR
$2.02B
| $100K | ﹤0.01% |
2,853
-447
| -14% | -$17.3K |
2025 Q3
1 quarter
|
|
4504
ProShares Ultra QQQ
QLD
$15.4B
| $100K | ﹤0.01% |
1,422
-118
| -8% | -$8.36K |
2023 Q3
9 quarters
|
|
4505
FT Vest US Equity Buffer ETF March
FMAR
$1.19B
| $99.8K | ﹤0.01% |
2,102
-2,370
| -53% | -$111K |
2024 Q3
5 quarters
|
|
4506
CALL
Coca-Cola Europacific Partners
CCEP
$44.4B
| $99.8K | ﹤0.01% |
+1,100
| New | +$99.4K |
2025 Q4
0 quarters
|
|
4507
PUT
DexCom
DXCM
$32.2B
| $99.6K | ﹤0.01% |
1,500
-34,900
| -96% | -$2.26M |
2024 Q3
5 quarters
|
|
4508
Suzano
SUZ
$10.5B
| $99.5K | ﹤0.01% |
10,650
| – | – |
2024 Q2
6 quarters
|
|
|
CV
4509
CapsoVision Inc
CV
$328M
| $97.7K | ﹤0.01% |
9,136
+943
| +12% | +$6.53K |
2025 Q3
1 quarter
|
|
4510
Alto Ingredients
ALTO
$292M
| $96.8K | ﹤0.01% |
33,605
-648
| -2% | -$1.22K |
2022 Q1
15 quarters
|
|
4511
AirSculpt Technologies
AIRS
$128M
| $96.7K | ﹤0.01% |
48,843
+25,461
| +109% | +$155K |
2022 Q1
15 quarters
|
|
4512
Nerdy
NRDY
$65M
| $96.1K | ﹤0.01% |
6,163
+546
| +10% | +$9.23K |
2022 Q1
15 quarters
|
|
4513
GSK
GSK
$94.2B
| $96.1K | ﹤0.01% |
1,959
-47,797
| -96% | -$2.23M |
2013 Q2
50 quarters
|
|
|
FLNA
4514
Filana Therapeutics
FLNA
$45M
| $96K | ﹤0.01% |
48,462
+48,371
| +53,155% | +$155K |
2020 Q2
22 quarters
|
|
4515
Wrap Technologies
WRAP
$90.8M
| $95.8K | ﹤0.01% |
+40,245
| New | +$97K |
2025 Q4
0 quarters
|
|
4516
State Street SPDR S&P Insurance ETF
KIE
$542M
| $95.8K | ﹤0.01% |
+1,592
| New | +$93.7K |
2025 Q4
0 quarters
|
|
4517
FT Vest US Equity Enhance & Moderate Buffer ETF January
XJAN
$43.3M
| $95.3K | ﹤0.01% |
2,588
-3,124
| -55% | -$114K |
2024 Q3
5 quarters
|
|
4518
Chegg
CHGG
$81.9M
| $94.9K | ﹤0.01% |
102,087
-430
| -0.4% | -$469 |
2016 Q2
38 quarters
|
|
4519
AllianzIM US Equity 6 Month Floor5 Jan/Jul ETF
FLJJ
$8.64M
| $94.4K | ﹤0.01% |
2,947
| – | – |
2025 Q1
3 quarters
|
|
4520
Roundhill Generative AI & Technology ETF
CHAT
$1.96B
| $94.3K | ﹤0.01% |
1,600
-65,660
| -98% | -$4.07M |
2025 Q3
1 quarter
|
|
4521
Nautilus Biotechnolgy
NAUT
$249M
| $94.1K | ﹤0.01% |
48,254
| – | – |
2022 Q1
15 quarters
|
|
4522
Aemetis
AMTX
$124M
| $93.8K | ﹤0.01% |
67,455
+67,453
| +3,372,650% | +$136K |
2023 Q3
9 quarters
|
|
4523
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$10.9B
| $92.5K | ﹤0.01% |
2,736
| – | – |
2023 Q2
10 quarters
|
|
4524
FT Vest US Equity Deep Buffer ETF September
DSEP
$381M
| $92.3K | ﹤0.01% |
+2,056
| New | +$91.4K |
2025 Q4
0 quarters
|
|
4525
CALL
Unilever
UL
$129B
| $92.1K | ﹤0.01% |
+1,408
| New | +$94.6K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.